Stock Events

abrdn Life Sciences Investors 

$15.07
55
-$0.3-1.95% Thursday 20:00

Statistics

Day High
15.38
Day Low
15.06
52W High
15.63
52W Low
10.39
Volume
211,777
Avg. Volume
101,712
Mkt Cap
412.17M
P/E Ratio
0
Dividend Yield
12.74%
Dividend
1.92

Upcoming

Dividends

12.74%Dividend Yield
10Y Growth
0.33%
5Y Growth
5.5%
3Y Growth
2.69%
1Y Growth
44.09%

Earnings

3JunExpected
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q3 2022
Q1 2024
-3.03
-1.58
-0.13
1.32
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HQL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
VanEck Biotech
BBH
Mkt Cap454.74M
VanEck Biotech ETF focuses on biotechnology, a core area for HQL, making it a direct competitor in the life sciences investment space.
iShares Biotechnology
IBB
Mkt Cap7.71B
iShares Biotechnology ETF invests in biotechnology and pharmaceuticals, directly competing with HQL's life sciences and biotech investment focus.
SPDR Biotech
XBI
Mkt Cap7.47B
SPDR S&P Biotech ETF has a broad biotech focus, directly competing with HQL's investment strategy in the life sciences sector.
First Trust NYSE Arca Biotechnology Index Fund
FBT
Mkt Cap1.15B
First Trust NYSE Arca Biotechnology Index Fund is focused on biotechnology, competing with HQL's life sciences and biotech investments.
Invesco Biotechnology & Genome
PBE
Mkt Cap256.41M
Invesco Dynamic Biotechnology & Genome ETF competes by investing in biotech, a key area of focus for HQL.
Virtus LifeSci Biotech Products
BBP
Mkt Cap22.19M
Virtus LifeSci Biotech Products ETF focuses on biotech product companies, competing with HQL's life sciences investment strategy.
Principal Healthcare Innovators
BTEC
Mkt Cap16.18M
Principal Healthcare Innovators Index ETF invests in healthcare innovation, including biotech, competing with HQL's focus.
ARK Genomic Revolution
ARKG
Mkt Cap1.35B
ARK Genomic Revolution ETF focuses on genomics, a niche within HQL's broader life sciences investment scope, making it a competitor.
ALPS Medical Breakthroughs
SBIO
Mkt Cap114.42M
ALPS Medical Breakthroughs ETF invests in medical breakthroughs, often in biotech, competing with HQL's investment focus.
Amplify Treatments Testing and Advancements
GERM
Mkt Cap9.55M
ETFMG Treatments, Testing and Advancements ETF focuses on companies involved in the treatment and testing of diseases, a subset of the life sciences sector where HQL operates.

About

Miscellaneous
Investment Trusts/Mutual Funds
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Show more...
CEO
Country
US
ISIN
US87911K1007

Listings